Genmab continued to expand its presence in the antibody-drug conjugate (ADC) field with a deal to buy ProfoundBio for $1.8 billion in cash. The transaction will give Genmab three clinical programmes, including the FRα-targeted, Topo1 ADC rinatabart sesutecan (Rina-S).
Jan van de Winkel, CEO of Genmab, noted that the purchase “firmly aligns with our long-term strategy,” adding that “ProfoundBio’s ADC candidates, proprietary technology platforms and talented team will be a great addition.” The transaction is expected to close this quarter.
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.